Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...357358359360361362363364365366367...401402»
  • ||||||||||  Journal:  POSSIBLE ROLE OF NUTRITION IN PREVENTION OF SARCOPENIA AND FALLS. (Pubmed Central) -  Nov 29, 2019   
    Nutritional factors, as well as exercise can help with both prevention and treatment of sarcopenia. In this review, we analyze the foundation of sarcopenia as potentially modifiable risk factor for falls, and we try to formulate practical strategies for nutritional interventions aimed at reducing the risk for sarcopenia and falls in our elderly patients.
  • ||||||||||  Review, Journal:  Nutritional Intervention in Chronic Liver Failure. (Pubmed Central) -  Nov 29, 2019   
    Nutrition intervention should be stepped up from nutrition counselling to oral nutritional supplements, to enteral tube feeding, or to parenteral nutrition as appropriate. As in other malnourished patients, the prevention of refeeding syndrome or vitamin/trace element deficiency should be taken care of.
  • ||||||||||  Clinical, Review, Journal:  Cachexia and Sarcopenia in Older Adults with Cancer: A Comprehensive Review. (Pubmed Central) -  Nov 29, 2019   
    Efforts to develop targeted pharmacologic therapies with cachexia have not been successful thus far. Formal treatment guidelines, an updated consensus definition for cancer cachexia and the development of a widely adapted assessment tool, much like the GA utilized in geriatric oncology, could help advance the field of cancer cachexia over the next decade.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  ExPrEs: Assessing The Effects of Exercise, Protein, and Electric Stimulation On Intensive Care Unit Patients Outcomes (clinicaltrials.gov) -  Nov 29, 2019   
    P=N/A,  N=60, Active, not recruiting, 
    Formal treatment guidelines, an updated consensus definition for cancer cachexia and the development of a widely adapted assessment tool, much like the GA utilized in geriatric oncology, could help advance the field of cancer cachexia over the next decade. Trial completion date: Oct 2019 --> Jun 2020 | Trial primary completion date: Aug 2019 --> Jun 2020
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  Counteracting Age-related Loss of Skeletal Muscle Mass (CALM) (clinicaltrials.gov) -  Nov 29, 2019   
    P=N/A,  N=66, Completed, 
    Trial completion date: Oct 2019 --> Jun 2020 | Trial primary completion date: Aug 2019 --> Jun 2020 Recruiting --> Completed | Trial completion date: Feb 2019 --> Aug 2019 | Trial primary completion date: Jan 2019 --> Jun 2019
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  Counteracting Age-related Loss of Skeletal Muscle Mass (clinicaltrials.gov) -  Nov 29, 2019   
    P=N/A,  N=208, Completed, 
    Recruiting --> Completed | Trial completion date: Feb 2019 --> Aug 2019 | Trial primary completion date: Jan 2019 --> Jun 2019 Recruiting --> Completed | Trial completion date: Feb 2019 --> Aug 2019 | Trial primary completion date: Jan 2019 --> Jun 2019
  • ||||||||||  Journal:  Physical exercise, nutrition and hormones: three pillars to fight sarcopenia. (Pubmed Central) -  Nov 28, 2019   
    Optimization of these factors may increase their efficiency; however, scientific data may be sometimes confusing so far. Therefore, we aim to give practical advices to clinician to identify and to highlight the most important aspects in each of these three factors that should be addressed.
  • ||||||||||  Review, Journal:  Emerging awareness on the importance of skeletal muscle in liver diseases: time to dig deeper into mechanisms! (Pubmed Central) -  Nov 27, 2019   
    We then discuss the implication of skeletal muscle compartment in non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH), focusing on plausible metabolic disruption in muscle compartment that might participate in NAFLD progression. Finally, we discuss shortcomings and challenges we need to address in the near future prior to designate the muscle compartment as a therapeutic target in CLD.
  • ||||||||||  Review, Journal:  The impact of dietary protein intake on longevity and metabolic health. (Pubmed Central) -  Nov 27, 2019   
    However, malnutrition, including sarcopenia/frailty due to inadequate protein intake, is harmful to longevity/metabolic health. Therefore, further study is necessary to elucidate the specific restriction levels of individual AAs that are most effective for longevity/metabolic health in humans.
  • ||||||||||  Journal:  Current pharmacotherapies for sarcopenia. (Pubmed Central) -  Nov 27, 2019   
    Few drugs have been developed specifically for sarcopenia and many have failed to meet clinically relevant outcomes related to strength and physical performance. The multifactorial complexity of sarcopenia means that tailored, personalised treatments are more likely to be required than just a single intervention.
  • ||||||||||  Sarcopenia in chronic pancreatitis and it's corrrelation with physical functioning and quality of life (P4) -  Nov 24, 2019 - Abstract #APDW2019APDW_1033;    
    The patients with sarcopenia were having a low overall quality of life, especially in domains related to systemic symptoms and activity Sarcopenia in chronic pancreatitis is not recognised by assessment of conventional anthropometric parameters in the majority of patients which is associated with reduced physical functioning and QOL and should be evaluated.
  • ||||||||||  Colorectal Cancer and the Obesity Paradox (P7) -  Nov 24, 2019 - Abstract #APDW2019APDW_794;    
    Obesity was seen in 299 patients (20%). The rate of obesity did not increase within the investigation period.
  • ||||||||||  Impact Of Sarcopenia On Clinical Outcome Of Cirrhotic Patients (P4) -  Nov 24, 2019 - Abstract #APDW2019APDW_289;    
    Sarcopenia predisposes to HE and infectious complications mainly SBP. Incorporating sarcopenia in the conventional prognostic factors had added value, particularly in compensated and early decompensated cirrhosis.
  • ||||||||||  Sarcopenia as a prognostic marker in patient with liver cirrhosis (P1) -  Nov 24, 2019 - Abstract #APDW2019APDW_153;    
    The current study is largest and most comprehensive study that gives the cut off values of Muscle mass, strength and performance in patients of Child C Cirrhosis. Muscle strength and performance correlated with mortality.
  • ||||||||||  Journal:  Sarcopenic Obesity Revisited: Insights From the Mr and Ms Os Cohort. (Pubmed Central) -  Nov 23, 2019   
    The SIR is a key hallmark of progressive nutritional and functional decline leading to poorer survival in patients with cancer. ASM/TBF may be used in geriatric screening to detect sarcopenic obesity, to guide implementation of weight control, as well as in muscle-strengthening programs.
  • ||||||||||  Retrospective data, Journal:  SARC-F for Screening of Sarcopenia Among Older Adults: A Meta-analysis of Screening Test Accuracy. (Pubmed Central) -  Nov 23, 2019   
    ASM/TBF may be used in geriatric screening to detect sarcopenic obesity, to guide implementation of weight control, as well as in muscle-strengthening programs. Although the screening sensitivity performance of SARC-F was poor, its specificity was high; thus, it is an effective tool for selecting subjects who should undergo further testing for confirming a diagnosis of sarcopenia.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    SARCOPENIA AND IMMUNOTHERAPY RESPONSE IN PRETREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) () -  Nov 23, 2019 - Abstract #AIOM2019AIOM_85;    
    Patients and We included 110 patients affected by advanced NSCLC treated with ICIs (pembrolizumab or nivolumab) and at least one previous line of chemotherapy. Sarcopenia at baseline could be a predictor of worse outcome in patients with advanced NSCLC receiving ICIs.